Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.
Since Nov 19, 2025
Transactions
32
Purchases
0
Sales
32
Purchase value
$0.00
Sale value
$1.07M
Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.
Dan PatersonDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Nov 5, 2026Period of report Nov 3, 20260001104659-26-123510
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleNov 3, 2026
Common StockF1
1,299
$9.60
$12.47K
651,413
Direct
Filing footnotes · 1
F1The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of RSUs.
Filed Oct 2, 2026Period of report Sep 30, 20260001104659-26-113362
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Daniel CalkinsChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Oct 2, 2026Period of report Sep 30, 20260001104659-26-113361
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Daniel CalkinsChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Sep 23, 2026Period of report Sep 21, 20260001104659-26-110070
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dan PatersonDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Aug 5, 2026Period of report Aug 3, 20260001104659-26-091172
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dan PatersonDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Jun 24, 2026Period of report Jun 22, 20260001104659-26-077333
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Daniel CalkinsChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Jun 24, 2026Period of report Jun 22, 20260001104659-26-077332
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dan PatersonDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed May 6, 2026Period of report May 4, 20260001104659-26-056226
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dan PatersonDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Feb 5, 2026Period of report Feb 4, 20260001104659-26-010891
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dan PatersonDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Jan 14, 2026Period of report Jan 12, 20260001104659-26-003789
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Daniel CalkinsChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Jan 14, 2026Period of report Jan 12, 20260001104659-26-003787
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Daniel CalkinsChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Dec 29, 2025Period of report Dec 24, 20250001104659-25-124695
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Brian M StuglikDirector
4Rule 10b5-1 plan disclosed
Filed Dec 18, 2025Period of report Dec 16, 20250001104659-25-122579
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dan PatersonDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Dec 18, 2025Period of report Dec 16, 20250001104659-25-122578
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Robert E. GagnonDirector
4Rule 10b5-1 plan disclosed
Filed Dec 18, 2025Period of report Dec 16, 20250001104659-25-122576
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dan PatersonDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Dec 12, 2025Period of report Dec 10, 20250001104659-25-120709
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dan PatersonDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Dec 9, 2025Period of report Dec 5, 20250001104659-25-119712
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dan PatersonDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Dec 4, 2025Period of report Dec 2, 20250001104659-25-118490
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dan PatersonDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Dec 1, 2025Period of report Nov 26, 20250001104659-25-117345
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Dan PatersonDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Nov 25, 2025Period of report Nov 21, 20250001104659-25-116059
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Paul A. BunnDirector
4Rule 10b5-1 plan disclosed
Filed Nov 25, 2025Period of report Nov 21, 20250001104659-25-116061
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
Michael KauffmanDirector
4Rule 10b5-1 plan disclosed
Filed Nov 25, 2025Period of report Nov 21, 20250001104659-25-116060
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
Sale
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.
Oct 1, 2026
Common StockF2
44,121
$8.00
$352.97K
652,712
Direct
Filing footnotes · 2
F1The reported securities were subject to a performance restricted stock units ("RSU") award that was granted on January 21, 2026. 106,893 RSUs vested on September 30, 2026, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria related to certain clinical development goals had been achieved.
F2The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of RSUs.
F1The reported securities were subject to a performance restricted stock units ("RSU") award that was granted on January 21, 2026. 106,893 RSUs vested on September 30, 2026, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria related to certain clinical development goals had been achieved.
F2The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of RSUs.
F1The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
F2The total number of shares beneficially owned includes 831 shares of common stock acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan.
F1The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
F1The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
F1The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
F1The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
F1The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
F1The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
F1The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
F1The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
F1The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
F1The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
F1The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.00 through $10.01, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
F3The stock option vested in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion vested). The first eleven installments vested beginning on the last day of the month over the period from June, 2024 to April, 2025 and the last installment vested on the day before the 2025 Annual Meeting of Stockholders.
F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.00 through $10.01, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.